Medichem to enter and explore the injectable business

Introduction

Medichem Solutions S.L. is the division of Medichem, a family-owned, popular international pharmaceutical company. The company is an expert in manufacturing and establishing Finished Dosage Forms and Active Pharmaceutical Ingredients. Medichem concentrates on generics and is crowned for its flagship in Octenidine and Chlorhexidine products. Company invest its 10% of its yearly turnover in R&D.

Breckenridge Pharmaceutical, Inc. is a leading pharmaceutical company develop, commercialize and sells quality generic drugs. The company’s spectacular portfolio involves products for rare diseases, supportive care, autoimmune and oncology conditions. The company is also engaged in smart collaborations with infinite manufacturers to bolster its business and footprint.

Announcement

Breckenridge and Medichem confirmed their partnership deal, where Breckenridge will extend its injectable business, continuing with its existing dedication in the U.S. hospital channel. While Medichem will be receiving a box full of manufacturing responsibility for injectable products used throughout the therapeutic sector, like emergency drugs, critical care and anesthesia. Together, the company is sharing a mutual goal, working for the same mission of introducing reliability and high-quality solutions to the hospital settings for the patients in urgent need of a solution.

An equal opportunity

It’s an equal opportunity for both Medichem and Breckenridge as they are at the transforming and exploring stage. For Medichem, it’s a different business line that may lead to something bigger and positive in the future, complementing the company’s long-standing vision. Breckenridge is thereby all set to extend the hospital portfolio to meet the needs of genuine patients who are out of access to the treatments.

The company wants to cover a massive population so that they at least have access to the solution for the extreme conditions. With this, the company will provide significant therapeutic solutions and stay with the patients in their tough treatment stages.

Leaders’ Excitement

Chief Commercial Officer and President of Breckenridge, Brian Guy, said, “This partnership is a huge support to our company’s emerging footprint in the hospital setting. It also marks a valuable milestone in our smart strategy and era in three areas of patient-centric businesses like retail, hospital and specialty.”

Chief Commercial Officer of Medichem, Olga Urazova, said, “We are very thrilled to join hands with Breckenridge for the first products which will be manufactured at our promising close to heart facility in Asturias, Spain. This site integrates sterile fill-and-finish potential to the company’s B2B platform and a contribution to partners for extending their pipeline.”